<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04635956</url>
  </required_header>
  <id_info>
    <org_study_id>CNET-PD1</org_study_id>
    <nct_id>NCT04635956</nct_id>
  </id_info>
  <brief_title>Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas</brief_title>
  <official_title>Anti-PD-1 Antibody Camrelizumab Combined With Cisplatin/Paclitaxel/Bevacizumab for Recurrent or Advanced Cervical Neuroendocrine Carcinomas: A Single Arm, Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrent or advanced cervical neuroendocrine carcinoma (NEC) is refractory to multimodal&#xD;
      treatment, even to extensive therapy. Chemotherapy, consisting of platinum and etoposide,&#xD;
      remains the main therapy for recurrent or advanced cervical NEC. In addition, bevacizumab has&#xD;
      shown progression-free benefits in recurrent or advanced cervical cancer. Case report&#xD;
      suggested anti-PD-1 antibody may have antitumor activities in NEC. Based on these evidences,&#xD;
      a phase 2, single arm trial is conducted to explore the objective response rate (ORR) of&#xD;
      platinum/etoposide/bevacizumab/anti-PD-1 antibody (camrelizumab) for the treatment of&#xD;
      recurrent or advanced cervical NEC. This trial is to enroll 20 patients, who would accept 6&#xD;
      courses of platinum/etoposide/bevacizumab/camrelizumab. If the patient achieved complete or&#xD;
      partial remission, a total period of 12 months bevacizumab/camrelizumab will be given as&#xD;
      maintain therapy. The primary endpoint is ORR. The second endpoints are severe adverse events&#xD;
      according to criteria of Common Terminology Criteria for Adverse Events (CTCAE) and iRECIST&#xD;
      Guideline, and critical changes of laboratory testing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2020</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Intervention of platinum/etoposide/bevacizumab/camrelizumab</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>1 years</time_frame>
    <description>proportion of partial or complete remission after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>severe adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>grade 3/4 adverse events and mortality according to criteria of Common Terminology Criteria for Adverse Events (CTCAE) and iRECIST Guideline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a composite changes of important laboratory testing</measure>
    <time_frame>1 year</time_frame>
    <description>these changes include liver/kidney/myocardiac functions, insulin resistance, functions of adrenal gland</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chemotherapy</condition>
  <condition>Anti-pd-1 Antibody</condition>
  <condition>Cervical Neuroendocrine Carcinoma</condition>
  <condition>Adverse Drug Event</condition>
  <condition>Recurrent Cervical Carcinoma</condition>
  <condition>Advanced Cervical Carcinoma</condition>
  <condition>Objective Response Rate</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will accept therapy consisting of platinum/etoposide/bevacizumab/camrelizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug therapy</intervention_name>
    <description>6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed recurrent or advanced cervical neuroendocrine carcinoma&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  No immunosuppressive disease&#xD;
&#xD;
          -  Signed an approved informed consents&#xD;
&#xD;
          -  Performance status of ECOG 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not meeting all of the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, M.D.</last_name>
    <phone>+86-139-1198-8831</phone>
    <email>lilleigh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming Wu, M.D.</last_name>
    <phone>+86-138-0122-4549</phone>
    <email>wuming@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>8613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 15, 2020</study_first_submitted>
  <study_first_submitted_qc>November 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 15, 2020</last_update_submitted>
  <last_update_submitted_qc>November 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

